



**RECEIVED**  
**CENTRAL FAX CENTER**

**JAN 31 2005**

**FACSIMILE**

PLEASE CALL US AT (703) 413-3000 IF THE MESSAGE YOU RECEIVE IS INCOMPLETE OR NOT LEGIBLE

ATTORNEYS AT LAW

FOURTH FLOOR  
1755 JEFFERSON DAVIS HIGHWAY  
ARLINGTON, VIRGINIA 22202  
USA

(703) 413-3000  
(703) 413-2220 FACSIMILE

OBLONPAT@OBLON.COM

PATENT, TRADEMARK AND COPYRIGHT LAW  
AND RELATED FEDERAL AND ITC LITIGATION

WWW.OBLON.COM

TO	Examiner Saidha	January 11, 2005 /1/21/05
NAME	PTO	DATE
COMPANY/FIRM		FAX #
NUMBER OF PAGES INCLUDING COVER: 4		CONFIRM FAX: <input type="checkbox"/> YES <input type="checkbox"/> NO
FROM	Thomas M. Cunningham	220738US
NAME	703-412-6563	OUR REFERENCE
DIRECT PHONE #		10/088,092
YOUR REFERENCE		

**MESSAGE**

Dear Examiner Saidha:

Thank you for the signed and initialed copy of the IDS filed 3/21/02. We are still missing a signed copy of the IDS filed 3/10/2003 which lists (6) documents. Please find attached a copy of this IDS for your convenience.

Would you sign and return fax this 1449 to us?

Please call me if you have any questions.

With best regards,

Thomas M. Cunningham

Unless otherwise indicated or obvious from the nature of the transmittal, the information contained in this facsimile message is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error or are not sure whether it is privileged, please immediately notify us by telephone and return the original message to us at the above address via the U.S. Postal Service at our Expense. Thank You.

Dept.: NFO/smp FF

Due Date: 03/10/03

OSMM&amp;N File No. 220738US0PCT

Serial No. 10/088,092

In the matter of the Application of: Jun ISHIZAKI et al.

For: A GENE ENCODING NOVEL HUMAN SECRETORY TYPE  
PHOSPHOLIPASE A2

The following has been received in the U.S. Patent Office on the date stamped hereon:

 Check for Assignment: 2 pages/PTO 1595 Information Disclosure Statement Cited References (6) Dep. Acct. Order Form Statement of Relevancy PTO-1449 European Search Report Cited Pending  
Applications IDS/Related/List of Related Cases**Rec'd PCT/PTO 10 MAR 2003**

Received: \_\_\_\_\_

Docket No. 220738US0PCT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Jun ISHIZAKI, et al.

SERIAL NO: 10/088,092

FILED: March 21, 2002

FOR: A GENE ENCODING NOVEL HUMAN SECRETORY TYPE PHOSPHOLIPASE A2

GAU:

EXAMINER:

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

## REFERENCES

The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.

A check is attached in the amount required under 37 CFR §1.17(p).

## RELATED CASES

Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.

A check is attached in the amount required under 37 CFR §1.17(p).

## CERTIFICATION

Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made a reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

## DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

22850

\_\_\_\_\_  
Norman F. Oblon  
Registration No. 24,618Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 03/02)\_\_\_\_\_  
Surinder Sachar  
Registration No. 34,423

SHEET 1 OF 1

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 220738US0PCT		SERIAL NO. 10/088,092	
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT		Jun ISHIZAKI, et al.			
		FILING DATE		March 21, 2002 GROUP			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
	AO				YES	NO	
	AP						
	AQ						
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	AR	JUN ISHIZAKI et al.: "Cloning and characterization of novel mouse and human secretory phospholipase A2s" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 35, pages 24973-24979 08/27/99					
	AS	Y. YOKOTA et al.: "Suppression of murine endotoxic shock by sPLA2 inhibitor, indoxam, through group IIA sPLA2-independent mechanisms" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1438, no. 2, pages 213-222 05/18/99					
	AT	E.D. MIHELICH et al.: "Structure-based design of a new class of anti-inflammatory drugs: secretory phospholipase A2 inhibitors, SPI" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1441, no. 2-3, pages 223-228 11/23/99					
	AU	E.A. DENNIS: "The growing phospholipase A2 superfamily of signal transduction enzymes" TIBS TRENDS IN BIOCHEMICAL SCIENCES, vol. 22, no. 1, pages 1-2 1997					
	AV	G. LAMBEAU et al.: "Receptors for a growing family of secreted phospholipase A2" TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 20, no. 4, pages 162-170 04/99					
	AW	Noriko SUZUKI et al.: "Structures, enzymatic properties, and expression of novel human and mouse secretory phospholipase A2s" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 8, pages 5785-5793 02/25/00				<input type="checkbox"/> Additional References sheet(s) attached	
Examiner				Date Considered			
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							